RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer

Dana-Farber Cancer Institute

Status and phase: Completed; Phase 2

Conditions: Pancreatic Cancer

Treatments: Drug: RAD001

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00409292

06-197

Details and patient eligibility

About

The purpose of this research study is to investigate if RAD001 is an effective treatment for pancreatic cancer that has spread and not responded to treatment. Experiments have shown that RAD001 can prevent cells from multiplying. RAD002 has also been tested in laboratory experiments imitating cancer conditions and the results have been promising.

Full description

• Participants taking part in this research study will be given a study medication-dosing calendar for each treatment cycle. Each cycle lasts four weeks during which you will be taking the study drug, RAD001, orally every day.
• Participants will come into the clinic every other week during the time of enrollment. At each clinic visit blood work will be taken to monitor the participants health and a physical exam will be performed. CT scans will be repeated every 2 months to assess the tumor.
• Participants will remain on the study as long as they continue to benefit from the study medication.

Enrollment: 33 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologic confirmation of pancreatic adenocarcinoma
• 18 years of age or older
• At least one measurable site of disease according to RECIST criteria that has not been previously irradiated. If patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation.
• Treated with gemcitabine-based chemotherapy with documented tumor progression on gemcitabine or intolerance to gemcitabine.
• Prior treatment with no more than 1 prior chemotherapy regimen for metastatic disease.
• Minimum of two weeks since any major surgery, completion of radiation, or completion of all prior systemic anti-cancer therapy.
• ECOG performance status 0-1.
• Life expectancy of greater than 12 weeks.
• Adequate bone marrow and liver function.
• Must be able to swallow tablets.

Exclusion criteria

• Prior treatment with an investigational drug within the preceding 4 weeks.
• Prior treatment with an inhibitor of mTOR
• Chronic treatment with systemic steroids or another immunosuppressive agent
• More than one prior chemotherapy treatment for metastatic disease
• Uncontrolled brain or leptomeningeal metastases, including patient who continue to require glucocorticoids for brain or leptomeningeal metastases.
• Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin
• Patients with chronic renal insufficiency
• Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study.
• Known history of HIV seropositivity
• Impairment of gastrointestinal function or gastrointestinal disease that my significantly alter the absorption of RAD001.
• Active, bleeding diathesis or an oral vitamin K antagonist medication
• Women who are pregnant or breast feeding

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

33 participants in 1 patient group

RAD001

Experimental group

Description:

RAD001 was administered continuously at a dose of 10 mg daily by mouth until disease progression, unacceptable toxicity, or withdrawal of consent. Four weeks of study drug was considered to be one cycle of treatment.

Treatment:

Drug: RAD001